Indigo Diabetes appoints Paul Moraviec as Chairman of the Board

12 May 2021

  • Brings decades of leadership experience in the Global MedTech sector

  • As CEO of ConvaTec Group Plc, led the $4.5 billion IPO on the London Stock Exchange

  • Transformed Abbott’s Diabetes Care EMEA division

Ghent, Belgium: 12 May 2021 – Indigo Diabetes NV, a pioneering developer of medical solutions using nanophotonics, is pleased to announce the appointment of Paul Moraviec as Chairman of its Board of Directors. Paul has amassed over three decades of global experience in the healthcare sector, having held multiple senior leadership positions. Most recently Paul led the ConvaTec Group Plc, a global medical products and technologies company, as Chief Executive Officer, orchestrating a successful company turnaround and subsequent $4.5 billion IPO on the London Stock Exchange in 2016, which at the time was the largest healthcare listing in Europe. In addition, he brings highly relevant diabetes experience, having been Vice President of Abbott’s Diabetes Care International division between 2002 and 2007 where he transformed the EMEA business with low single digit growth and declining market share, to the fastest growing company in the glucose monitoring field. Paul has also led the early-stage surgical robotics company Prosurgics, redesigning their product development and commercialisation strategy; and led a major restructuring and performance improvement program across UK, Germany and France for Johnson & Johnson’s Neuro Surgery business. Paul will replace Harrold van Barlingen who will step down as Chairman and retain a seat on the Board as a Non-Executive Director.

More information on Indigo Diabetes’ website.